BOSUTINIB, SUNITINIB, TIVOZANIB, IMATINIB, NILOTINIB, REBASTINIB OR BAFETINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS
申请人:KYOTO UNIVERSITY
公开号:EP3789027A1
公开(公告)日:2021-03-10
The present invention provides a compound for use in the prophylaxis and/or treatment of amyotrophic lateral sclerosis (ALS), wherein said compound is selected from the group consisting of bosutinib, sunitinib, tivozanib, imatinib, nilotinib, rebastinib and bafetinib. Particularly, using a compound already on the market as a pharmaceutical product, a pharmaceutical product for the prophylaxis or treatment of ALS can be developed rapidly at a low cost.
本发明提供了一种用于预防和/或治疗肌萎缩性脊髓侧索硬化症(ALS)的化合物,其中所述化合物选自由博苏替尼、舒尼替尼、替沃扎尼、伊马替尼、尼洛替尼、瑞帕替尼和巴非替尼组成的组。特别是,利用已作为药品上市的化合物,可以低成本快速开发预防或治疗 ALS 的药品。